Key facts, as of
As of November 6, 2026, Zimmer Biomet (ZBH) trades at $105.59, up 19.3% over the past year. Its 52-week range runs from $79.12 to $112.55; the price is 6.2% below that high. It is 39.7% below its all-time high of $175.11, reached in April 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +0.4%, against +316.3% for the S&P 500 (SPY). It sits 14.7% above its 200-day average of $92.03, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 53.6% annualized, which we rate very high risk. It has a trailing P/E of 26.7 and a dividend yield of 0.91%.
Cite: Portfolio Terminal, "Zimmer Biomet (ZBH) stock analysis", 2026-11-06. https://portfolio-terminal.com/analyse/zbh
Where it trades today
trading 79% of the way up its 52-week range
How the price has moved
How far it is from its record
Zimmer Biomet (ZBH) is 39.7% below its all-time high of $175.11, reached in April 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +0.4%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- ZBH closes above its 50-day average ($95.12), and the 50-day sits above the 200-day ($92.03): on both averages the chart reads as an uptrend.
- At $105.59, ZBH is 6.2% below its 1-year high of $112.55, set on November 4, 2026, and 33.5% above its 1-year low of $79.12 (May 11, 2026).
- Over the past month ZBH rose 18.8%, from $88.88 to $105.59.
- ZBH trades at 26.7x its last twelve months of earnings and 11.8x the next twelve months' estimate, so analysts expect earnings 126.8% higher.
- Its P/E is 23.2% below the 34.7x median of the 3 other medical devices companies we track (ABT, SYK, BSX).
- ZBH's 30-day volatility, 53.6% a year, works out to a typical daily move of about 3.4%.
- Yahoo Finance puts its beta at 0.47: over five years of monthly returns, ZBH moved about 0.47% for each 1% move of the S&P 500.
What would change the read
- A close under the 50-day average, $95.12 (−9.9% from the last close), would turn the read to a pullback; under the 200-day, $92.03 (−12.8%), the longer rise is in question.
- A close above $112.55 (+6.6%) would be a new 1-year high; below $79.12 (−25.1%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for ZBH, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under medical devices among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for ZBH by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for ZBH. Last refresh: Nov 8, 2026, 10:53 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Medical Devices.
What Zimmer Biomet does
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for…
What analysts expect
ZBH carries a hold consensus from 21 analysts, with an average price target of $115.62 versus $105.59 today (+9.5%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ZBH generated $8.57B in trailing revenue (3.1% year over year), with a 9.0% net margin, and $1.44B of free cash flow, against $7.23B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $8.23B | $5.74B | $1.36B | $705.10M | $3.56 | $1.42B |
| 2024 | $7.68B | $5.49B | $1.53B | $903.80M | $4.45 | $1.14B |
| 2023 | $7.39B | $5.31B | $1.45B | $1.02B | $4.91 | $1.19B |
| 2022 | $6.94B | $4.92B | $1.19B | $231.40M | $1.10 | $1.07B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
ZBH is in 14 of the 54 ETFs we track. It weighs most in XLV: 0.28% of the fund, holding #49 of 62.
How its figures compare with those peers
Companies in the same industry
ZBH beside the other companies Yahoo Finance files under medical devices among the assets we track (ABT, SYK, BSX, largest first).
ZBHyou are here$105.59$19.98B
ABTAbbott Laboratories$109.93$190.39B
SYKStryker Corporation$325.87$124.06B
BSXBoston Scientific$42.75$61.96BWhat the chart is saying
In an uptrend, 6.2% under its 1-year high with no resistance above.
uptrend- Price is 11.0% above its 50-day average and 14.7% above its 200-day.
- The 50-day crossed above the 200-day on 2026-08-13 (a “golden cross”).
- RSI at 64 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $102.07 (-3.3%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is ZBH valued right now?
Zimmer Biomet trades at 26.7 times its last twelve months of earnings and 11.8 times the next twelve months' estimate (Yahoo Finance, November 6, 2026). On the chart: in an uptrend, 6.2% under its 1-year high with no resistance above. Price is 11.0% above its 50-day average and 14.7% above its 200-day.
What is the risk level of ZBH?
Based on 30-day volatility of 53.6%, ZBH has VERY HIGH risk. Its beta of 0.47 means it has swung less than the S&P 500 over the last five years.
Does ZBH pay dividends?
Yes, Zimmer Biomet has a dividend yield of 0.91%.
How far is ZBH from its all-time high?
Zimmer Biomet is 39.7% below its all-time high of $175.11, reached in April 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +0.4%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold ZBH?
14 of the 54 popular ETFs we track hold Zimmer Biomet. The largest weights: XLV (0.28%), VB (0.21%), RSP (0.20%), SPY (0.03%) and IVV (0.03%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is ZBH?
0.03%, as of September 30, 2026: ZBH is holding #407 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.26 in Zimmer Biomet.
What is the analyst price target for ZBH?
The average analyst price target for Zimmer Biomet (ZBH) is $115.62 based on 21 analyst estimates, about 9.5% above the current price of $105.59. The published range runs from $97.00 to $130.00.
How much revenue does ZBH generate?
Zimmer Biomet reported $8.57B in trailing twelve-month revenue. Revenue growth is running at 3.1% year over year. Net margin sits at 9.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare ZBH with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.